Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday.

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...

WACKER and BENEO have launched 2’-Fucosyllactose (2’-FL), a human milk oligosaccharide (HMO), for early-life nutrition. Available initially i ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

European indexes fell and markets were set for a moody Monday after Moody's downgraded U.S. sovereign debt last week. "This is a major symbolic move as Moody's were the last of the major rating ...

Investing.com -- GSK plc (LON: GSK ), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma.